Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Aug 25 (Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.